Hims & Hers Health, Inc. (NYSE:HIMS) Shares Purchased by Royce & Associates LP

Royce & Associates LP raised its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 17.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 341,000 shares of the company’s stock after acquiring an additional 49,500 shares during the period. Royce & Associates LP owned 0.16% of Hims & Hers Health worth $6,281,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its position in Hims & Hers Health by 113.1% during the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after purchasing an additional 3,205,108 shares during the period. Farallon Capital Management LLC lifted its stake in Hims & Hers Health by 3,890.5% in the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after buying an additional 1,634,000 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in shares of Hims & Hers Health by 164.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock valued at $10,663,000 after acquiring an additional 328,142 shares during the period. State of Michigan Retirement System grew its position in shares of Hims & Hers Health by 177.8% during the second quarter. State of Michigan Retirement System now owns 500,000 shares of the company’s stock worth $10,095,000 after acquiring an additional 320,000 shares during the last quarter. Finally, Carnegie Investment Counsel acquired a new stake in shares of Hims & Hers Health in the 3rd quarter worth about $5,531,000. 63.52% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on HIMS. TD Cowen boosted their target price on shares of Hims & Hers Health from $25.00 to $28.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Needham & Company LLC started coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective for the company. Deutsche Bank Aktiengesellschaft raised their target price on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. Bank of America lowered Hims & Hers Health from a “buy” rating to an “underperform” rating and reduced their price target for the stock from $32.00 to $18.00 in a research report on Thursday. Finally, Piper Sandler reissued a “neutral” rating and set a $21.00 price target (up from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health has an average rating of “Hold” and a consensus target price of $20.71.

Insider Activity

In related news, insider Soleil Boughton sold 2,345 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.65, for a total transaction of $34,354.25. Following the completion of the sale, the insider now directly owns 159,796 shares in the company, valued at approximately $2,341,011.40. This trade represents a 1.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Patrick Harrison Carroll sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $22.07, for a total transaction of $331,050.00. Following the completion of the transaction, the insider now owns 196,941 shares in the company, valued at approximately $4,346,487.87. This represents a 7.08 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 996,961 shares of company stock worth $20,256,416 over the last 90 days. 17.71% of the stock is owned by company insiders.

Hims & Hers Health Stock Down 7.3 %

HIMS opened at $19.32 on Monday. The firm has a market cap of $4.15 billion, a PE ratio of 43.91 and a beta of 1.06. The business has a fifty day simple moving average of $19.76 and a 200-day simple moving average of $18.92. Hims & Hers Health, Inc. has a fifty-two week low of $7.40 and a fifty-two week high of $30.44.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. During the same quarter last year, the business posted ($0.04) EPS. Hims & Hers Health’s revenue was up 77.1% on a year-over-year basis. On average, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.